Influenza News and Research

Latest Influenza News and Research

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

Cerus Corporation announced today that it has entered into a collaborative agreement with France's national transfusion service, the Etablissement Français du Sang (EFS), for the development of the company's INTERCEPT Blood System for red blood cells.

10 Feb 2010

VSV has potential to be genetically modified to serve as anti-cancer agent

Vesicular stomatitis virus, or VSV, has long been a model system for studying and understanding the life cycle of negative-strand RNA viruses, which include viruses that cause influenza, measles and rabies.

10 Feb 2010

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

10 Feb 2010

Loyola University Chicago offers new research-intensive program for healthcare industry

Registration is underway for Loyola University Chicago's new infectious disease & immunology master's degree program that will prepare graduates for challenging health-related positions in government, research and private industry.

10 Feb 2010

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.

9 Feb 2010

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Novavax, Inc. announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains.

9 Feb 2010

Dana-Farber Cancer Institute and Sanford-Burnham Medical Research Institute sign license agreement with Genentech

Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses. These viruses include the strains for the current seasonal and H1N1 influenzas. Genentech and Roche also have a non-exclusive right to manufacture, develop and market diagnostic tests for group 1 influenza.

9 Feb 2010

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

Cerus Corporation announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells continued to circulate 24 hours following transfusion. The INTERCEPT red blood cell system is a pathogen inactivation treatment the company is developing to protect against transmission of infectious diseases through red blood cell transfusions. An estimated 70 million units of red blood cells are transfused worldwide each year.

9 Feb 2010

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

8 Feb 2010

Novavax to discontinue collaboration agreement with ROVI Pharmaceuticals

Novavax, Inc. announced today that the company has decided to discontinue negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals to develop Novavax's virus-like-particle (VLP)-based vaccines against influenza in the country of Spain.

8 Feb 2010

Majority of Americans believe flu outbreak is over; levels of concern continue to decline

The latest poll from researchers at the Harvard School of Public Health (HSPH) shows that almost half of Americans believe the H1N1 flu outbreak is over (44%), and levels of concern about getting sick with the virus continue to decline.

6 Feb 2010

Breakthrough discovery could help in developing a broad spectrum of antiviral drugs

Within a virus's tiny exterior is a store of energy waiting to be unleashed. When the virus encounters a host cell, this pent-up energy is released, propelling the viral DNA into the cell and turning it into a virus factory.

6 Feb 2010

CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF

Solvay Pharmaceuticals, Inc. announced that Phase IIIb data published in the January issue of Clinical Therapeutics confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food.

5 Feb 2010

Virginia Tech professor wins grant to formulate mathematical framework for flu prevention

An assistant professor with the Virginia Tech College of Engineering has won a $750,000 federal grant to formulate a mathematical framework that can track the spread of pandemics among populations and malware across wireless computer networks, as well as how a blackout occurring on one major power grid can cause a cascade of additional neighboring networks to fail.

5 Feb 2010

Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Biota Holdings Limited today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009.

5 Feb 2010

Tecan Group, Enigma Diagnostics sign manufacturing and supply agreement for Enigma ML instruments

The Tecan Group, a leading global provider of laboratory instruments and solutions, and Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the signing of a manufacturing and supply agreement for Enigma's ML instruments.

From Tecan 5 Feb 2010

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

BioCryst Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.

4 Feb 2010

Amantadine binds to and blocks critical M2 proton channel necessary for influenza virus to infect healthy cells

Antiviral drugs block influenza A viruses from reproducing and spreading by attaching to a site within a proton channel necessary for the virus to infect healthy cells, according to a research project led by Iowa State University's Mei Hong and published in the Feb. 4 issue of the journal Nature.

4 Feb 2010

Providing Tamiflu and educating on sanitizer use helped to stop spread of H1N1 at boys' summer camp

Providing preventive Tamiflu and educating and emphasizing the need for repeated hand sanitizer use and disinfectant spray helped stop the spread of H1N1 influenza at a boys' summer camp in northern Alabama, according the co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases.

4 Feb 2010

Vaccination against seasonal influenza produces protective immune response in infants

Vaccination against seasonal influenza is safe and produces a protective immune response in infants as young as 6 to 12 weeks, concludes a study in the February issue of The Pediatric Infectious Disease Journal.

4 Feb 2010

Influenza News and Research

Latest Influenza News and Research

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

VSV has potential to be genetically modified to serve as anti-cancer agent

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

Loyola University Chicago offers new research-intensive program for healthcare industry

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Dana-Farber Cancer Institute and Sanford-Burnham Medical Research Institute sign license agreement with Genentech

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Novavax to discontinue collaboration agreement with ROVI Pharmaceuticals

Majority of Americans believe flu outbreak is over; levels of concern continue to decline

Breakthrough discovery could help in developing a broad spectrum of antiviral drugs

CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF

Virginia Tech professor wins grant to formulate mathematical framework for flu prevention

Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Tecan Group, Enigma Diagnostics sign manufacturing and supply agreement for Enigma ML instruments

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

Amantadine binds to and blocks critical M2 proton channel necessary for influenza virus to infect healthy cells

Providing Tamiflu and educating on sanitizer use helped to stop spread of H1N1 at boys' summer camp

Vaccination against seasonal influenza produces protective immune response in infants

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Influenza News and Research

Latest Influenza News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in